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S246 Poster Session I2006 to April 2010, total 44 patients with refractory/recurrent AML
were enrolled. The median age was 29 (2 to 51) years old. The me-
dian blasts in bone marrow (BM) were 36% (20% to 92%) before
conditioning. The donors were identical siblings (6) or unrelated
ones (9) or haploidentical family members (29). Conditioning regi-
ments were individualized according to patients’ status. Usually,
the regimen with high-dose cytarabine plus BUCY/CYTBI was
used (20). The patients with impaired organ function received above
regimen except using fludarabine instead of cyclophosphamide (16).
For the recipients with more than 40% blasts in BM, in order to re-
duce leukemia burden, melphalan (2) was added into above regimen
or FLAG that followed by reduced-intensified BUCY (6) was em-
ployed. GVHD prophylaxis was reported previously (DP Lu et al.,
Blood 2006;107:3065). Prophylactic immunotherapy including
DLI, DC-CIK, NK cells, IL-2, IFN-a, thymosin was used in the pa-
tients (11) who were lack of GVHD 120 days post-HSCT. All but
two patients attained durable engraftment. The incidence of grade
II to IV aGVHD and cGVHD were 32.2%, 59.1%, respectively.
With median follow-up 11 (1-46) months, the relapse rate was
25.1%. Thirty of 44 (68.2%) patients have been in complete remis-
sion since salvaged HSCT. One-year disease-free survival and over-
all survival were 68.5%, 70.4%, respectively. Our clinical results
have shown that the combination of salvaged HSCT and prophylac-
tic immunotherapy is a promising modality for treatment of refrac-
tory/recurrent AML, even with high leukemia burden.251
BONE MARROW STOMA SECRETES A SOLUBLE FACTOR THAT PROTECTS
LEUKEMIA CELLS FROM CYTARABINE INDUCED APOPTOSIS BY BLOKING
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Introduction: Despite a high response rate to chemotherapy, the
vast majority of patients with AML are destined to relapse due to re-
sidual disease in the bone marrow (BM). The tumor microenviron-
ment is increasingly being recognized as a critical factor in
mediating cancer development and drug resistance. Leukemia cell
mobilization in vivo by the CXCR4 inhibitor, AMD3100 induced
chemosensitization to AraC, which translated into a significant
survival advantage in mice (Nervi et al., 2009).
Objectives: In vitro evaluation of the mechanisms involved in leuke-
mia cell chemoprotection to AraC-induced apoptosis mediated by
bone marrow stroma.
Results: A leukemia mouse cell line generated by knocking in the
human PML-RARa cDNA (APL) was cultured with or without
BM stroma supernatant (BMS; obtained from the BM stroma cell
line M2-10B4) and treated with AraC for 24 hours. FACS analysis
showed that BMS induced a significant and selective chemoprotec-
tion to Arac (25% vs 65% apoptosis respectively). There was no pro-
tection observed with other cytotoxic agents such as cisplatin,
etoposide, 5-FU, Gemtuzumab or radiotherapy. BMS did not mod-
ify the APL cell cycle status (CFSE, PI). AraC enters the cell via the
ENT (equilibrative nucleoside transporter). To verify whether the
soluble factor exerts an effect over the ENT, the activity of thismem-
brane transporter was investigated in samples with APL cultured
alone or cultured with BMS for 24 hours by the incorporation of ra-
dioactive adenosine. Interestingly, the data showed there is a 50% re-
duction in ENT activity, without changes in ENT mRNA or ENT
protein expression. This effect was confirmed by using the ENT in-
hibitor, NBMPR. Detection of caspase-3 activity was performed to
confirm apoptosis mediated by AraC, and the results confirmed
that the chemoprotection by the soluble factor causes a significant
reduction of caspase-3 activity and apoptosis. Cytotoxicity studies
by the MTT assay revealed that the inhibition of ERK (U0126) in
APL cells cultured with BMS significantly reverted the protection
and sensitized the cells to AraC treatment.
Conclusion: The BM stroma secretes a soluble factor(s) that
significantly protect APL cells from AraC-induced apoptosis by par-
tially blocking ENT activity and by activation of MAPK (ERK) in-
tracellular signaling pathways associated with cell survival andproliferation. Strategies that modify leukemia/BM microenviron-
ment interaction may potentially improve leukemia patient
outcomes.252
IMPROVED SURVIVAL OF PATIENTS WITH ACUTE MYELOID LEUKEMIA
WITH NORMAL CYTOGENETICS AND FLT3-ITD MUTATION AFTER ALLO-
GENEIC HEMATOPOIETIC CELL TRANSPLANT: CONCURRENT NPM1
MUTATION NOT ASSOCIATED WITH BETTER OUTCOMES
Loh, Y., How, G.F., Hwang, W., Linn, Y.C., Goh, Y.T., Diong, C.P.,
Wong, G.C., Lim, L.C. SingaporeGeneral Hospital, Singapore, Singapore
Background: Acute myeloid leukemia (AML) with normal cytoge-
netics (CN) is a heterogenous disease with an increasing number
of molecular mutations demonstrated in recent years. The FLT3 in-
ternal tandem duplication (FLT3-ITD) has been associated with ad-
verse outcomes; while outcomes of NPM1-mutated AML have been
favorable. The interplay between the various mutations remains to
be fully elucidated and hence the decision on which patients with
CN AML would benefit from an allogeneic transplant in first
complete remission (CR1) is in flux.
Aims: We undertook an analysis of the outcomes of adult patients
with AML to determine the impact of FLT3 ITD and NPM1 on
outcomes. We assessed whether complete response rate (CR), re-
lapse rate, OS and cumulative probability of relapse following che-
motherapy, autologous or allogeneic transplant are affected by the
presence of these mutations.
Methods:This is a retrospective analysis of adult CN AML patients
treated between 2003 and 2008. In our center, patients in CR1 below
age 50 years who have a sibling donor are usually offered an alloge-
neic transplant. Those who do not, either undergo consolidation
with high dose cytarabine or an autologous transplant. Patients
with poor risk features such as needing more than one cycle to
achieve CR are considered for an unrelated donor allograft if a suit-
able donor is found.
Results: Fifty-three patients with median age 51 years (15-61 years)
were treated. Of these, 20 underwent autologous, 9 sibling and 7
URD transplants while the rest received chemotherapy alone. The
frequency of mutations was FLT31/NPM1 (n 5 12) FLT1/
NPM- (n 5 10), FLT-/NPM1 (n 5 8), FLT-/NPM- (n 5 12), ei-
ther unknown (n 5 11). At a median duration of follow up of 22
months (0-78months) the probability of OS among FLT31 patients
was significantly different based on treatment type: sibling 66.7% vs.
URD 20.8% vs. autologous 13.8% vs. chemotherapy 0% (p \
0.001). Among FLT31/NPM- patients, the overall survival based
on treatment type: sibling 100% vs. auto and chemo 0% (p 5
0.001) while for FLT1/NPM1 patients: allograft 50% vs. autolo-
gous 22% (p 5 0.012). The numbers of patients with FLT-/
NPM1 were too few to analyze.
Conclusions: The presence of FLT3 ITD confers an adverse prog-
nosis on patients with CN AML but our data suggests a sibling allo-
graft may ameliorate this. The concurrent presence of NPM1
mutation with FLT3 does not appear to abrogate the adverse impact
and such patients should also be offered an allograft.253
MULTIPLEX REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION
AS A DIAGNOSTIC DEVICE AND PREDICTIVE OF SURVIVAL FOR ACUTE
LEUKEMIA
Park, J.S., Ahn, M.S., Jeong, S.H. Ajou University School of Medicine,
Suwon, Kyunggi-do, Korea
In addition to conventional G-banding technique, multiplex re-
verse transcriptase polymerase chain reaction (mRT-PCR) could
be applied for the documentation of cytogenetic aberrations in diag-
nosing acute leukemia. The bone marrow samples from 276 patients
with acute leukemia were examined with mRT-PCR and the results
were compared with conventional cytogenetics with regard to com-
patibility and survival outcome. Concordance rate between G-band-
ing and mRT-PCR was 49.5%. G-banding did not detect
chromosomal aberrations that were documented with mRT-PCR
in 20.3% of patients as opposed to 27.9% of patients, vice versa. Fa-
vorable cytogenetic aberrations such as t(15;17), t(8;21), and inv(16)
Poster Session I S247were detected not by G-banding but by mRT-PCR in 20 patients
and unfavorable aberrations including t(9;22), t(11;19), t(4;11), and
t(1;19) were detected by mRT-PCR, not by G-banding, in 14
patients. On the other hand, mRT-PCR could not detect various
complexities in 55 patients. Unfavorable aberrations detected by
G-banding, not by mRT-PCR, showed relatively poor survival out-
comes in chemotherapy group and transplant group (p 5 0.053 and
0.004, respectively). Favorable aberrations detected by mRT-PCR
should be considered as good prognosis even G-banding technique
did not detect any aberrations (p 5 0.023). However, the difference
has abolished by autologous or allogeneic hematopoietic stem cell
transplantation. mRT-PCR technique can be a complementary
diagnostic tool of acute leukemia when combined with conventional
cytogenetics and the molecular result is predictable for the prognosis
and the resultant survival.254
A PHASE I STUDY OF GEMTUZUMAB OZOGAMICIN IN COMBINATION
WITH A MYELOABLATIVE CONDITIONING (MAC) REGIMEN AND
ALLOSCT IN CHILDREN WITH HIGH-RISK CD331 AML: A NEW TAR-
GETED IMMUNOCHEMOTHERAPY CONDITIONING REGIMEN (GO-BU/CY)
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Background: Children with high-risk AML (induction failure [IF],
re-induction failure after relapse [RIF], refractory relapse [RR],
3rd complete remission [CR3]) have dismal outcomes (overall sur-
vival [OS] 10-20%) (Michallet et al. BMT, 2000; Shenoy et al.
BMT 2008). Over 80% of AML patients express CD33. Gemtuzu-
mab Ozogamicin (GO) alone and in combination with chemother-
apy is safe and active in childhood AML.
Objectives: To determine the safety, maximum tolerated dose
(MTD) and efficacy of GO in combination with busulfan/cyclophos-
phamide (BU/CY) followed by AlloSCT.
Methods:GOwas administered on Day -14 at doses of 3.0, 4.5, 6.0,
7.5 mg/m2, and BU Days -7, -6, -5, -4 at doses of 12.8-16.0 mg/kg,
and CY Days -3, and -2 at doses of 60 mg/kg followed by allogeneic
hematopoietic stem cell transplantation (AlloSCT). GVHDprophy-
laxis consisted of tacrolimus/mycophenolate mofetil.
Results: Twelve patients: 5-IF, 2-RIF, 4-RR,1-CR3; median age:
3yrs (range 1-17) withmedian follow-up of 1379d (939-2305) in alive
patients. Nine UCBT (3 each HLA 6/6-, 5/6-, 4/6-match), 2 MUD
(10/10) and 1 MSD. 3 patients each at GO doses of 3.0, 4.5, 6.0, or
7.5 mg/m2. No dose-limiting toxicities secondary to GO were ob-
served. Day 100 transplant related mortality was 0%. Neutrophil
and platelet engraftment was observed in 92% and 75% of patients
at median day 22 (12-40) and 42 (21-164), respectively. Median
day 130 donor chimerism was 99% (85-100%). The probability of
grade II-IV aGVHD was 42% while cGVHD was 28%. Seven of
12 patients relapsed, 5 have died from progressive disease, 6 year
event-free survival (EFS) and OS was 33% (CI9510-58%) and 50%
(CI9521-73%), respectively.
Conclusion: GO combined with a MAC regimen followed by Al-
loSCT is well-tolerated in children with high-risk AML and is asso-
ciated with improved EFS and OS compared to historical controls.
The safe and tolerable dose of GO at 7.5mg/m2 will be studied in
a phase II clinical trial under an IND.255
OUTCOMES OF PATIENTS WITH AML WHO UNDERGO SECOND
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT OR DONOR
LYMPHOCYTE INFUSION
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Objective: Second allogeneic hematopoietic stem cell transplants
(SCT) and donor lymphocyte infusions (DLI) are used to treat pa-
tients who relapse after initial SCT. DLI can also be used to induce
graft-versus-host disease (GVHD) or promote donor chimerism. To
better understand prognostic factors in this population, we reviewed
our institutional experience with second allogeneic SCT/DLI in
AML patients.
Methods: We performed a retrospective review of AML patients
who received either a second allogeneic SCT or DLI from 1991
through 2009. Progression-free survival (PFS) and overall survival
(OS) were estimated by the Kaplan-Meier method, with day of sec-
ond HSCT/DLI defined as day 0. The COX proportional hazards
method was used to determine the individual impact of the following
factors at second HSCT/DLI on OS: age, sex, interval from initial
transplant, remission status, stem cell graft (CD341) vs. DLI
(CD31), related vs. unrelated donor, GVHD prophylaxis, and
development of acute or chronic GVHD.
Results: 37 AML patients (20 females, 17 males) received a second
HSCT or DLI. Median age was 53 years (range 24-69). 17 (46%)
patients received stem cells, the rest DLI. Twenty two (50%) had re-
lated donors. Median interval from the initial SCT to second SCT/
DLI was 99 days (range 21-1227).
SecondHSCT/DLIwas performed for relapsed/persistent disease
(79%), graft failure (11%), and poor chimerism (11%). Prior to sec-
ond HSCT/DLI, 34% were in complete remission (CR). After sec-
ondHSCT/DLI, 66% of 32 evaluable patients were in CR. 14 of 34
evaluable patients (41%) developed acute GVHD, while 3 (9%) de-
veloped chronic GVHD. Univariate analysis did not reveal any pa-
tient factors that significantly impacted OS. The estimated median
PFS and OS were 65 days (95% CI 38-106) and 103 days (95% CI
56-165), respectively.
For patients retransplanted/given DLI for relapsed AML, OS at
100 days, 1 year, and 2 years were 48%, 23%, and 12% respectively.
As shown in Table 1, better OS was seen in patients who relapsed.
200 days versus\100 days after initial SCT. Of 32 deaths, 10 (31%)
were treatment related, 21 (66%) were disease related, and 1 (3%)
was unknown.
Table 1. Overall survival following second allogeneic SCT/DLI
stratified by time of relapse after first SCT.
Time of relapse after first SCT 100 Day 1 Year 2 Year<100 days 33% 13% 0%
100-200 days 63% 13% 0%
>200 days 88% 50% 25%Conclusion: A second HSCT or DLI offers a chance at remission
for some AML patients who relapse after prior allogeneic SCT.
However treatment related mortality is high. Further exploration
of additional strategies is needed to optimize outcomes of this group
of patients.256
PHASE I TRIAL OF ESCALATED DOSES OF TARGETED MARROW RADIA-
TION DELIVERED BY TOMOTHERAPY COMBINED WITH ETOPOSIDE
AND CYCLOPHOSPHAMIDE; AN ALLOGENEIC HCT PREPARATIVE REGI-
MEN FOR PATIENTS WITH ADVANCED LEUKEMIA
Stein, A.S., Wong, J., O’Donnell, M.R., Synder, D.S., Palmer, J.M.,
Tsai, N.-C., Parker, P., Farol, L., Spielberger, R., Sahebi, F.,
Kogut, N., Forman, S. City of Hope Medical Center, Duarte, CA
Overall survival (OS) for acute leukemia in relapse (RL) or induc-
tion failure (IF) treated with HSCT is 16-19% [Duval et al
JCO.2010]. While randomized studies have shown a dose response
relationship, with higher doses of radiation resulting in decreased re-
lapse, this benefit is offset by increased mortality. We report the ini-
tial results of a Phase I trial of 12 patients transplanted between 3/
2008 and 7/2010 in which escalated doses of targeted whole body ra-
diation to marrow bearing areas delivered by Tomotherapy on days
-10 to -6 was added to etoposide 60mg/kg [adj bw] day -5 and
